Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989099 · ClinicalTrials.gov registry record · Phase 2
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
A Phase 2 study of Lymphedema, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06989099 is a Phase 2 study of Lymphedema that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06989099, a Phase 2 study of Lymphedema, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.
Conditions Studied
Interventions
- PROCEDURE Immediate Lymphatic Reconstruction (ILR)/
- PROCEDURE Prophylactic Lymphovenous Bypass (pLVB)
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06989099
The ClinicalTrials.gov registry entry for NCT06989099 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which Immediate Lymphatic Reconstruction (ILR)/ is the first listed.
NCT06989099 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06989099 about?
NCT06989099 is a clinical study titled "Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.". To learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.
What is the current status of trial NCT06989099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-09-24. Estimated completion is 2029-08-01.
What conditions does trial NCT06989099 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT06989099?
The interventions under investigation include: Immediate Lymphatic Reconstruction (ILR)/ (PROCEDURE), Prophylactic Lymphovenous Bypass (pLVB) (PROCEDURE).
Who is sponsoring clinical trial NCT06989099?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989099 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
COMPLETED · Phase 2
-
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
COMPLETED · Phase 2
-
Pycnogenol for the Treatment of Lymphedema
COMPLETED · Phase 2
-
Lymphedema Surveillance Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.